Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

This is a post hoc analysis of the QUEST study. Baseline factors that positively impacted clinical remission odds on dupilumab included heightened blood eosinophil counts and fractional exhaled ...

Perspective from John Luo, MD Patients with dupilumab prescriptions for their atopic dermatitis had lower risks for psychiatric and sleep disorders than those prescribed other treatments ...

They include Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's own IL-5 inhibitor Fasenra (benralizumab), which competes with GlaxoSmithKline's Nucala (mepolizumab) and Teva's ...

A significant number of Americans experience chronic inflammatory skin conditions with no pinpointed cause and often no effective treatments beyond symptom management. Now a new study could pave ...

It was a two-state solution - a prospect which seems impossible today. If implemented, it would have created a Palestinian state on more than 94% of the occupied West Bank. The map Olmert had ...

According to Penadés, all of them made sense. The team had not even considered one of the solutions, and is now investigating it further. Co-scientist is a multi-agent AI system built using ...

Nature-based solutions are gaining traction in Sub-Saharan Africa, with investment growing by approximately 15% annually since 2012. However, funding remains a fraction of what is needed to build ...

Dupilumab is associated with a reduced risk of peripheral vascular disease, deep vein thrombosis, hypertension, type 2 diabetes mellitus, obesity, and hyperlipidemia within the first year of treatment ...

Dupilumab has been accepted for priority review by the US Food and Drug Administration (FDA) for the treatment of bullous pemphigoid (BP) in adults, according to a press release from the ...

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted a supplemental Biologics License Application for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP), a ...